UBS Says Generic GLP-1 Threat to Eli Lilly’s Long-Term Franchise Looks Limited
A UBS note cited by Yahoo Finance argues Eli Lilly’s GLP-1 pipeline advantage is likely to face only limited near-term pressure from generic versions of the drugs, keeping the company’s long-term franchise outlook broadly intact.